CTX1 is a p53 activator that overcomes HdmX-mediated p53 repression. CTX1 exhibits potent anti-cancer activity in a mouse acute myeloid leukemia (AML) model system
In Vitro
CTX1 binds directly to HdmX to prevent p53-HdmX complex formation, resulting in the rapidly induction of p53 in a DNA damage-independent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
CTX1 ( (30 mg/kg; i.p.; five days a week; for 3 weeks) significantly enhances the survival of mice in AML model system . CTX1 exhibited significant anti-cancer activity alone as well as in combination with nutlin-3 . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
